Brendan Payne joined SternIR in April of 2021 with 8+ years of biopharma Investor Relations experience as part of a 20+ year career in the life sciences sector.
Through roles in gene discovery, business development and venture capital, Brendan has gained a broad perspective on drug development from inception right through to pivotal trials. With a strong belief in empathy and critical thinking, Brendan prides himself on a thorough and thoughtful approach to message crafting and strategic targeting.
Before SternIR, Brendan was Director of Investor Relations at InMed Pharmaceuticals, Correvio Pharma, and Associate Director of Investor Relations at Aquinox Pharmaceuticals. In each role, Brendan delivered articulate and compelling investment theses to leading buy-side investors and sell-side Analysts. While fully heading in-house investor relations functions, he has executed on end-to-end IR plans, navigating through financings, key milestones and data events, including clinical successes and setbacks.
Brendan holds a Bachelor of Science in Genetics from the University of British Columbia and dual MBAs from Cornell and Queens Universities.
Brendan loves spectating his sons’ minor hockey and spending time with them skiing, cycling and camping. He is a voracious consumer of political satire, always with an eye on technology trends and global events. When not listening to the Munk Debates, he can be found searching for the latest easter eggs in the MCU.